Drug design of cyclin-dependent kinase 2 inhibitor for melanoma from traditional Chinese medicine

13Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

Abstract

One has found an important cell cycle controller. This guard can decide the cell cycle toward proliferation or quiescence. Cyclin-dependent kinase 2 (CDK2) is a unique target among the CDK family in melanoma therapy. We attempted to find out TCM compounds from TCM Database@Taiwan that have the ability to inhibit the activity of CDK2 by systems biology. We selected Tetrahydropalmatine, Reserpiline, and (+)-Corydaline as the candidates by docking and screening results for further survey. We utilized support vector machine (SVM), multiple linear regression (MLR) models and Bayesian network for validation of predicted activity. By overall analysis of docking results, predicted activity, and molecular dynamics (MD) simulation, we could conclude that Tetrahydropalmatine, Reserpiline, and (+)-Corydaline had better binding affinity than the control. All of them had the ability to inhibit the activity of CDK2 and might have the opportunity to be applied in melanoma therapy. © 2014 Hsin-Chieh Tang and Calvin Yu-Chian Chen.

Cite

CITATION STYLE

APA

Tang, H. C., & Chen, C. Y. C. (2014). Drug design of cyclin-dependent kinase 2 inhibitor for melanoma from traditional Chinese medicine. BioMed Research International, 2014. https://doi.org/10.1155/2014/798742

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free